- Page 1/1
- Next Page
This Missouri based ag company has entered into a merger that will expand its global footprint. Recently reported earnings were up 25% on the year. We like that cash reserves are growing, while the company aggressively retires debt. It trades at 9x earnings and 1.6x book, while supporting a 19% ROE. We recommend placing a stop-loss at $95, looking to achieve $136 -- upside potential of 19%. Yield 2.2%
(Analysts’ price target is $136.45)The company markets pulmonary hypertension treatment drugs. Recently reported earnings rose 117% on the year, beating estimates by 18%. Cash reserves are growing. The company trades at 12x earnings, under 2x book and supports a ROE of 17%. We recommend placing a stop-loss at $190, looking to achieve $284 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $284.60)Our PAST TOP PICK with GBT has triggered its stop at $14. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 11%, when combined with the previous buy indications.
Our PAST TOP PICK with GSY has triggered its stop at $116. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 5%, when combined with the previous buy indications.
- 1
- Next Page
This US homebuilder will benefit from calming inflation and interest rate movements. Management expects gross margins to be just under 25% and are guiding towards a 10% growth in sales next year. They have a good land position yet cycle through inventory effectively. We like that cash reserves are growing, while debt is retired and stock bought back. It trades at 9x earnings and 1.3x book. We recommend placing a stop-loss at $100, looking to achieve $141 -- upside potential of 20%. Yield 1.2%
(Analysts’ price target is $141.00)